Oxaliplatino Aurovit (Oxaliplatin)

Oxaliplatin is a platinum‑based chemotherapy drug that acts on the colorectal cancer treatment pathway.

• Metastatic colorectal cancer: Used in combination with fluoropyrimidine therapy to improve response rates and survival.
• Adjuvant colorectal cancer: Administered after surgical resection to reduce the risk of disease recurrence.
• Advanced gastrointestinal tumors: Utilized within multi‑drug protocols for disease control in selected cases.

• Oxaliplatin forms reactive platinum complexes that covalently bind to DNA, creating intra‑ and interstrand cross‑links that inhibit DNA replication and transcription. The resulting DNA damage triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly dividing tumor cells while sparing most normal tissues.

Oxaliplatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea and vomiting: Frequent episodes during or after infusion.
• Peripheral neuropathy: Tingling or numbness in the hands and feet, often dose‑related.
• Diarrhea: Loose stools that may require supportive care.
• Fatigue: Generalized tiredness affecting daily activities.
• Myelosuppression: Reduced blood cell counts, increasing infection risk.
• Elevated liver enzymes: Mild, transient rises in hepatic function tests.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: Anaphylaxis or bronchospasm during infusion.
• Acute neurotoxicity: Sudden onset of muscle cramps or jaw tightness.
• Thrombotic events: Blood clot formation in veins or arteries.
• Severe myelosuppression: Profound neutropenia or thrombocytopenia requiring hospitalization.
• Renal impairment: Deterioration of kidney function, especially with pre‑existing disease.
• Cardiac arrhythmias: Irregular heart rhythms observed during infusion.

When handling Oxaliplatino Aurovit, clinicians should observe standard oncology safety protocols and monitor patients closely.

• Renal function assessment: Evaluate baseline creatinine and adjust therapy if impairment is present.
• Neuropathy monitoring: Conduct regular neurological examinations to detect early signs of peripheral neuropathy.
• Hematologic surveillance: Perform routine complete blood counts to identify myelosuppression.
• Hepatic function checks: Monitor liver enzymes before each cycle.
• Pregnancy and lactation warning: Contraindicated in pregnant or breastfeeding individuals due to fetal toxicity.
• Store at ambient temperature: Keep vials in the original packaging, protect from light and moisture.

Oxaliplatin may interact with several concomitant medicines, requiring careful review of the patient’s medication list.

Major Interactions (Avoid)

• Nephrotoxic agents: Concurrent use with aminoglycosides or NSAIDs can worsen kidney injury.
• Anticoagulants anticoagulation: Increased bleeding risk when combined with warfarin or direct oral anticoagulants.\nModerate 

-       ").